Group Information: Members of the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group are listed in the eAppendix in the Supplement.
Submitted for Publication: July 9, 2013; final revision received January 27, 2014; accepted January 31, 2014.
Published Online: May 29, 2014. doi:10.1001/jamaophthalmol.2014.1019.
Study concept and design: Ying, Kim, Maguire, Flaxel, Martin.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Ying, Grunwald, Flaxel, Regillo.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Ying, Maguire, Huang, Rahhal.
Obtained funding: Maguire, Jaffe, Grunwald, Martin.
Administrative, technical, or material support: Daniel, Flaxel, Regillo.
Study supervision: Ying, Maguire, Daniel, Jaffe, Grunwald, Blinder, Regillo.
Conflict of Interest Disclosures: Dr Kim was an advisory board participant in 2012 for Allergan and Eyetech. Dr Regillo has served as a consultant to, received grants from, and served on the speaker’s bureaus for Genentech and Regeneron. Dr Blinder has served as a consultant to Ocusoft and served on the speaker’s bureaus for Bausch & Lomb and Genentech. No other disclosures were reported.
Funding/Support: This study was supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828 from the National Eye Institute, National Institutes of Health, US Department of Health and Human Services.
Role of the Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Previous Presentation: This study was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; May 7, 2013; Seattle, Washington.